Merck Announces Supply Agreement with U.S. Government for Molnupiravir

“In addition to this agreement with the U.S. government, we are actively engaged in numerous efforts to make molnupiravir available globally to fulfill Merck’s commitment to widespread access” said Rob Davis, president, Merck.

Merck, known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

“Merck is pleased to collaborate with the U.S. government on this new agreement that will provide Americans with COVID-19 access to molnupiravir – an investigational oral therapy being studied for outpatient use early in the course of disease – if it is authorized or approved,” said Rob Davis, president, Merck. “In addition to this agreement with the U.S. government, we are actively engaged in numerous efforts to make molnupiravir available globally to fulfill Merck’s commitment to widespread access.”

Through the agreement, if molnupiravir receives Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA), Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by the end of 2021.

Merck also plans to submit applications for emergency use or approval to regulatory bodies outside of the U.S. and is currently in discussions with other countries interested in advance purchase agreements for molnupiravir. Merck is committed to providing timely access to molnupiravir globally and intends to implement a tiered pricing approach based on World Bank data that recognizes countries’ relative ability to finance their public health response to the pandemic.

As part of its access strategy, Merck has also entered into non-exclusive voluntary licensing agreements for molnupiravir with established generic manufacturers to accelerate availability of molnupiravir in 104 low- and middle-income countries (LMICs) following approvals or emergency authorization by local regulatory agencies.

In addition to developing molnupiravir, Merck is contributing to the pandemic response by collaborating with Johnson & Johnson to support the manufacture of its COVID-19 vaccine.

This procurement of molnupiravir will be supported in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, in collaboration with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) under contract number W911QY21C0031.

Tags : #Latestpharmanews #LatestMercknews #Latestmercknews9June #COVID19treatment #Molnupiravir

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024
Transforming Patient Care: HealthTech Startups Making Waves in HealthcareOctober 30, 2024
Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024
Impressive Growth & Margin Expansion 237% YoY Surge in Net ProfitsOctober 29, 2024
Ramaiah Memorial Hospital Announces the Launch of its Comprehensive State-of-the-art Ramaiah Stroke Center on World Stroke Day October 29, 2024
CarDekho Group's New Auto Segment’s Festive Trend Report: SUVs Lead the Way with a 43% YoY Traffic Increase Across All Sub-SegmentsOctober 29, 2024
World Stroke Day by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.October 29, 2024
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024October 29, 2024
AI Gone Wild? Why OpenAI’s Whisper - Transcription Tool used in Hospitals Might Be Putting Lives at RiskOctober 29, 2024
India’s Humanitarian Aid to Palestine Amid Middle Eastern TurmoilOctober 29, 2024
A Race Against Time How World Stroke Day Highlights India’s Hidden Health CrisisOctober 29, 2024
Hester Biosciences Ltd Consolidated Net Profit in Q2FY25 up 108% Y-o-Y to Rs. 8.39 crore; Revenue up 19% to Rs. 83.69 croreOctober 28, 2024
Is Your Eye Surgery Safe? Inside Chhattisgarh’s Cataract Infection ScandalOctober 28, 2024
Can PM Modi’s 13,000 Crore Investment Reframe India’s Approach to Health?October 28, 2024
Herbalife India and IIT Madras Launch 1,000 Data Science Scholarships, Expanding Quality Education Access for Underserved CommunitiesOctober 28, 2024
American Oncology Institute (AOI) in Imphal Successfully Treats Advanced Thyroid Cancer CasesOctober 28, 2024
Beyond the Flare: Revolutionizing Psoriasis Care for a Brighter Tomorrow!October 28, 2024
Toxic Threat in Chennai’s Tiruvottiyur School: Inside the Mystery Gas Leak That Left Students HospitalizedOctober 26, 2024
Are You Scrolling Your Life Away? The Dark Reality of Digital AddictionOctober 26, 2024
Are You Scrolling Your Life Away? The Dark Reality of Digital AddictionOctober 26, 2024